Xilio Therapeutics (XLO) Other Accumulated Expenses (2020 - 2026)
Xilio Therapeutics (XLO) reported Other Accumulated Expenses of $198000.0 for Q1 2026, up 17.86% on a YoY basis from $168000.0 in Q1 2025, and up 138.55% sequentially from $83000.0 in Q4 2025.
Xilio Therapeutics (XLO) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Xilio Therapeutics (XLO) has 7 years of Other Accumulated Expenses data on file, last reported at $198000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Accumulated Expenses rose 17.86% year-over-year to $198000.0; the trailing twelve-month figure through Mar 2026 stood at $198000.0 (up 17.86% YoY), and the FY2025 full-year result was $83000.0, down 36.64% from the prior year.
- Other Accumulated Expenses rose to $198000.0 in Q1 2026, from $83000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $305000.0 in Q2 2022 to a low of $7000.0 in Q2 2024.
- A 5-year average of $132235.3 and a median of $109000.0 in 2024 frame the typical range for Other Accumulated Expenses.
- Across the five-year window, Other Accumulated Expenses tumbled 91.46% in 2024 and soared 2700.0% in 2025, its largest moves.
- Tracing XLO's Other Accumulated Expenses over 5 years: stood at $82000.0 in 2022, then slumped by 41.46% to $48000.0 in 2023, then jumped by 172.92% to $131000.0 in 2024, then sank by 36.64% to $83000.0 in 2025, then soared by 138.55% to $198000.0 in 2026.
- Business Quant data shows XLO's Other Accumulated Expenses at $198000.0 in Q1 2026, $83000.0 in Q4 2025, and $88000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Xilio Therapeutics | 148.60 Mn | -1.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 198,000.00 |
| Dec 31, 2025 | 83,000.00 |
| Sep 30, 2025 | 88,000.00 |
| Jun 30, 2025 | 196,000.00 |
| Mar 31, 2025 | 168,000.00 |
| Dec 31, 2024 | 131,000.00 |
| Sep 30, 2024 | 138,000.00 |
| Jun 30, 2024 | 7,000.00 |
| Mar 31, 2024 | 109,000.00 |
| Dec 31, 2023 | 48,000.00 |
| Sep 30, 2023 | 68,000.00 |
| Jun 30, 2023 | 82,000.00 |
| Mar 31, 2023 | 269,000.00 |
| Dec 31, 2022 | 82,000.00 |
| Sep 30, 2022 | 82,000.00 |
| Jun 30, 2022 | 305,000.00 |
| Mar 31, 2022 | 194,000.00 |
| Dec 31, 2021 | 321,000.00 |
| Sep 30, 2021 | 82,000.00 |
| Dec 31, 2020 | 82,000.00 |